Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec;6(Suppl 2):S103.
doi: 10.21037/atm.2018.11.41.

Translating L-2-HG to kidney cancer at the bench and bedside

Omran Abu Aboud  1 , Robert H Weiss  1   2   3
Affiliations
Editorial

Translating L-2-HG to kidney cancer at the bench and bedside

Omran Abu Aboud et al. Ann Transl Med. 2018 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Graphical representation of glutamine/2-HG pathway and therapeutics options in renal cancer based on Shelar et al. Glutamine is the source of 2-HG. Glutamine is metabolized to α-ketoglutarate (α-KG) with glutaminase-1 (GLS-1). IDH1 or 2 (IDH1/2) are involving in metabolizing α-KG to D-2-HG and malate dehydrogenase (MDH) or lactate dehydrogenase 1 (LDH1) will metabolize α-KG to L-2-HG. D-2-HG dehydrogenase (D2HGDH) and L-2HG dehydrogenase (L2HGDH) convert D-2-HG and L-2-HG to α-KG. A decrease in L2HGDH results in accumulation of the oncometabolite L-2-HG. In turn high L-2-HG inhibits activity of histone lysine demethylase 6A (KDM6A) to promote H3K27 trimethylation (H3K27Me3) in RCC cells. The glutaminase-1 (GLS-1) inhibitor CB-839 and MDH inhibitor (derivative of benzylpaullones) can be potential therapeutic targets for RCC. RCC, renal cell carcinoma.
See this image and copyright information in PMC

Comment on

References

    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. 10.1016/j.cell.2011.02.013 - DOI - PubMed
    1. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012;21:297-308. 10.1016/j.ccr.2012.02.014 - DOI - PMC - PubMed
    1. Wettersten HI, Aboud OA, Lara PN, Jr, et al. Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol 2017;13:410-9. 10.1038/nrneph.2017.59 - DOI - PubMed
    1. Shim EH, Livi CB, Rakheja D, et al. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov 2014;4:1290-8. 10.1158/2159-8290.CD-13-0696 - DOI - PMC - PubMed
    1. Hwang VJ, Kim J, Rand A, et al. The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. American Journal of Physiology: Renal Physiology 2015;309:F492-8. 10.1152/ajprenal.00238.2015 - DOI - PMC - PubMed